دورية أكاديمية
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
| العنوان: | Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. |
|---|---|
| المؤلفون: | Mohamedbhai SG; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS |
| المصدر: | British journal of haematology [Br J Haematol] 2012 Feb; Vol. 156 (4), pp. 516-22. Date of Electronic Publication: 2011 Dec 15. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Oxford : Blackwell Scientific Publications |
| مواضيع طبية MeSH: | Graft Rejection* , Hematopoietic Stem Cell Transplantation*/adverse effects , Lymphocyte Depletion* , Lymphocyte Transfusion* , Transplantation Chimera*, Antibodies, Monoclonal, Humanized/*therapeutic use , T-Lymphocytes/*drug effects, Adolescent ; Adult ; Aged ; Alemtuzumab ; Female ; Humans ; Leukemia/drug therapy ; Leukemia/therapy ; Lymphoma/drug therapy ; Lymphoma/therapy ; Male ; Middle Aged ; Retrospective Studies ; Transplantation, Homologous ; Young Adult |
| مستخلص: | The clinical significance of mixed chimerism following allogeneic haematopoietic stem cell transplantation (HSCT) remains controversial. Its relevance and incidence are probably influenced by the conditioning regimen and incorporation of T-cell depletion. The presence of recipient chimerism levels >40-50% following T-cell replete reduced intensity transplantation correlates with a high risk of graft rejection, regardless of donor-lymphocyte infusions, but it is unclear whether this finding translates to T-cell depleted transplants. We conducted a retrospective single-institution analysis of patients receiving alemtuzumab-based HSCT. 27/152 (18%) evaluable cases had predominantly recipient T-cell chimerism at 3 months or beyond. By contrast, coincident chimerism in the granulocyte lineage was predominantly of donor origin (median 100%) in all but one patient. Donor lymphocyte infusion effectively converted predominantly recipient T-cell chimerism to ful donor chimerism in all evaluable cases including three cases with no detectable donor T cells. The only graft failure occurred in the patient with predominantly recipient myeloid chimerism in whom rejection occurred rapidly before donor lymphocytes could be administered. We conclude that predominant or complete recipient T-cell chimerism following alemtuzumab-based regimens does not have the same clinical implications as that following T-cell replete transplants and can be effectively converted with donor lymphocytes without the need for lympho-depleting agents or re-conditioning. (© 2011 Blackwell Publishing Ltd.) |
| معلومات مُعتمدة: | United Kingdom Cancer Research UK; United Kingdom Department of Health |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 3A189DH42V (Alemtuzumab) |
| تواريخ الأحداث: | Date Created: 20111217 Date Completed: 20120430 Latest Revision: 20171116 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1111/j.1365-2141.2011.08944.x |
| PMID: | 22171699 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2141 |
|---|---|
| DOI: | 10.1111/j.1365-2141.2011.08944.x |